HMGB1 and paraplegia: Our 11 min ischemia model represents a reproducible and physiologically relevant platform for studying delayed paraplegia following SCI/R injury and offers a suitable preclinical framework for assessing the efficacy of anti-HMGB1 mAb administration as a therapeutic intervention.